Immune-related adverse events predict the therapeutic efficacy of pembrolizumab in urothelial cancer patients

被引：19
|
作者：
Kawai, Taketo [1 ]
Sato, Yusuke [1 ]
Makino, Katsuhiro [1 ]
Yamada, Yuta [1 ]
Nomiya, Akira [1 ]
Nakamura, Masaki [1 ]
Yamada, Daisuke [1 ]
Suzuki, Motofumi [1 ]
Igawa, Yasuhiko [1 ]
Kume, Haruki [1 ]
机构：
[1] Univ Tokyo, Grad Sch Med, Dept Urol, Tokyo, Japan
来源：
EUROPEAN JOURNAL OF CANCER | 2019年 / 116卷
关键词：
ASSOCIATION; NIVOLUMAB;
D O I：
10.1016/j.ejca.2019.05.017
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：114 / 115
页数：2
相关论文
共 50 条
  • [1] Association of Immune-Related Adverse Events with Pembrolizumab Efficacy in the Treatment of Advanced Urothelial Carcinoma
    Kobayashi, Kazuo
    Suzuki, Kenichi
    Hiraide, Makoto
    Aoyama, Takeshi
    Yokokawa, Takashi
    Shikibu, Sari
    Hashimoto, Koki
    Iikura, Yusuke
    Sato, Hitoshi
    Sugiyama, Erika
    Tajima, Masataka
    Hama, Toshihiro
    [J]. ONCOLOGY, 2020, 98 (04) : 237 - 242
  • [2] Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients
    Rogado, J.
    Sanchez-Torres, J. M.
    Romero-Laorden, N.
    Ballesteros, A., I
    Pacheco-Barcia, V
    Ramos-Levi, A.
    Arranz, R.
    Lorenzo, A.
    Gullon, P.
    Donnay, O.
    Adrados, M.
    Costas, P.
    Aspa, J.
    Alfranca, A.
    Mondejar, R.
    Colomer, R.
    [J]. EUROPEAN JOURNAL OF CANCER, 2019, 109 : 21 - 27
  • [3] CORRELATION BETWEEN IMMUNE-RELATED ADVERSE EVENTS SPECTRUM AND PROGNOSIS IN PATIENTS WITH ADVANCED UROTHELIAL CANCER TREATED WITH PEMBROLIZUMAB
    Tamiya, Takashi
    Kijima, Toshiki
    Tanaka, Hajime
    Yoshida, Soichiro
    Ishioka, Junichiro
    Matsuoka, Yoh
    Numao, Noboru
    Sakai, Yasuyuki
    Saito, Kazutaka
    Matsubara, Nobuaki
    Yuasa, Takeshi
    Masuda, Hithoshi
    Yonese, Junji
    Kageyama, Yukio
    Fujii, Yasuhisa
    [J]. JOURNAL OF UROLOGY, 2020, 203 : E743 - E744
  • [4] Immune-related adverse events (irAEs) predict therapeutic efficacy of an anti-PD-1 antibody in cancer patients
    Rogado, J.
    Romero Laorden, N.
    Sanchez Torres, J. M.
    Ballesteros Garcia, A. I.
    Pacheco-Barcia, V. E.
    Arranz, R.
    Mondejar Solis, R.
    Gullon, P.
    Lorenzo, A.
    Colomer Bosch, R.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [5] ASSOCIATION BETWEEN IMMUNE-RELATED ADVERSE EVENTS AND SURVIVAL OF PATIENTS WITH METASTATIC UROTHELIAL CARCINOMA TREATED WITH PEMBROLIZUMAB
    Nakamura, Kazutaka
    Toshio, Takagi
    Nemoto, Yuki
    Ishiyama, Yudai
    Ishihara, Hiroki
    Tachibana, Hidekazu
    Fukuda, Hironori
    Shinmura, Hiroaki
    Hashimoto, Yasunobu
    Kondo, Tsunenori
    Yoshida, Kazuhiko
    Iizuka, Junpei
    Ishida, Hideki
    Tanabe, Kazunari
    [J]. JOURNAL OF UROLOGY, 2022, 207 (05): : E28 - E28
  • [6] Retrospective study evaluating immune-related adverse events in cancer patients treated with pembrolizumab
    Mashni, Ola K.
    Baba, Dima W.
    Mahmoud, Aseel N.
    Qur'an, Tasnim O.
    [J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (03) : 577 - 581
  • [7] Immune-related Adverse Events in Cancer Patients
    Pallin, Daniel J.
    Baugh, Christopher W.
    Postow, Michael A.
    Caterino, Jeffrey M.
    Erickson, Timothy B.
    Lyman, Gary H.
    [J]. ACADEMIC EMERGENCY MEDICINE, 2018, 25 (07) : 819 - 827
  • [8] Impact of immune-related adverse events on the therapeutic efficacy of pembrolizumab in urothelial carcinoma: a multicenter retrospective study using time-dependent analysis
    Kawai, Taketo
    Taguchi, Satoru
    Nakagawa, Tohru
    Kamei, Jun
    Nakamura, Yu
    Obinata, Daisuke
    Yamaguchi, Kenya
    Kaneko, Tomoyuki
    Kakutani, Shigenori
    Tokunaga, Mayuko
    Uemura, Yukari
    Sato, Yusuke
    Enomoto, Yutaka
    Nishimatsu, Hiroaki
    Fujimura, Tetsuya
    Fukuhara, Hiroshi
    Takahashi, Satoru
    Kume, Haruki
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (02)
  • [9] Immune-related adverse events: pembrolizumab ± influenza vaccine
    [J]. Reactions Weekly, 2020, 1795 (1) : 8 - 8
  • [10] Immune-related adverse events in urothelial cancer patients: Adjustment for immortal time bias
    Otsuka, Hikari
    Kita, Yuki
    Ito, Katsuhiro
    Sano, Takeshi
    Inokuchi, Junichi
    Tomida, Ryotaro
    Takahashi, Atsushi
    Matsumoto, Kazumasa
    Kurahashi, Ryoma
    Ozaki, Yu
    Uegaki, Masayuki
    Maruyama, Satoru
    Mukai, Shoichiro
    Tsutsumi, Masakazu
    Kawahara, Takashi
    Segawa, Takehiko
    Kitamura, Hiroshi
    Morita, Satoshi
    Kobayashi, Takashi
    [J]. CANCER SCIENCE, 2022, 113 (11) : 3912 - 3921
12345